Top 5 Deals Of 2022: The Economic Drag On M&A Continues
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.
You may also be interested in...
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.
Pfizer's strategy for building a mega-blockbuster brand around Nurtec ODT involves establishing oral CGRPs as first-line treatment.